Novo Holdings A/S, a life science investor with a focus on long-term, sustainable value creation, has acquired Altasciences, a leading, fully-integrated, early drug development services platform, providing the pharma and biotech industries with a trusted partner for drug development, from preclinical safety testing through clinical proof-of-concept studies, from Audax Private Equity. Altasciences’ executive management team, led by CEO Chris Perkin, will continue to lead the business following the acquisition.
Abhijeet Lele, senior partner, head of principal investments in the U.S. at Novo Holdings, said, “The Altasciences team has done an impressive job of building an innovative company that plays an essential role in bringing innovative drugs to patients and is well-positioned to capture share in the fast-growing market for drug development services. We are excited about this investment and look forward to leveraging our network to continue growing Altasciences in collaboration with the management team.”
Chris Perkin, chief executive officer of Altasciences, added, “This is an exciting day for Altasciences. We are very pleased to be partnering with Novo Holdings in the next phase of our exciting journey, given their exceptional reputation, track record, and broad portfolio of high-growth healthcare companies. We look forward to continuing our ambitious growth plans and commitment to providing clients with value-added services that offer a new paradigm of drug development outsourcing.”
Goodwin Procter LLP served as legal advisor to Novo Holdings. Harris Williams served as lead financial advisor with Rothschild & Co. and Edgemont Partners serving as co-advisors to Altasciences. Kirkland & Ellis LLP served as legal advisor to Altasciences.